Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Acute 20Lymphoma, Non-Hodgkin 19Hodgkin Disease 18Multiple Myeloma 17Myelodysplastic Syndromes 16Lymphoma 16Graft vs Host Disease 16Lymphoma, Mantle-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Sarcoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Glioblastoma 11Tuberous Sclerosis 10Lymphoma, B-Cell, Marginal Zone 10Carcinoma, Renal Cell 10Neoplasms 9Hematologic Neoplasms 9Gliosarcoma 9Carcinoma, Hepatocellular 9Breast Neoplasms 9Brain Neoplasms 9Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Melanoma 8Burkitt Lymphoma 8Recurrence 7Neoplasm Metastasis 7

Interventions

AZD 6244 2ARQ 197 2veliparib 1temsirolimus 1sargramostim 1pegfilgrastim 1cixutumumab 1belinostat 1Topotecan 1Tolbutamide 1Sunitinib 1Sirolimus 1Rifampin 1Phantoms, Imaging 1Omeprazole 1Midazolam 1Magnetic Resonance Spectroscopy 1Ketoconazole 1Isotretinoin 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Gemcitabine 1Dextromethorphan 1Colony-Stimulating Factors 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adult Solid Neoplasm × Sirolimus × Clear all
NCT01625156 2015-10-20

Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
11 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡